Russia to postpone transfer of domestic pharma production to GMP-standards until 2016
The Russian government has decided to postpone until 2016 the requirement of domestic pharmaceutical production to Good Manufacturing Practices (GMP)-standards, according to the press service of the Russian Ministry of Health.
The transfer to GMP-standards is a serious need, as at present only 30% of drugs in the Russian market comply with international standards. Initially it was scheduled for January 2014, however, due to the current inability of many Russian drug producers to start production in accordance with GMP-standards it was suspended for two years.
It is planned that the Russian Ministry of Industry will be responsible for the control of production processes in accordance with the GMP-standards, while the Ministry of Health will track their use in clinical practice. In this regard, certificate of a pharmaceutical product will be provided by two state ministries.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze